Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度内部控制自我评价报告' which translates to '2019 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2019. The content includes detailed descriptions of internal control systems, evaluation scope, defect standards, and corrective actions. It is not a brief announcement or a certification letter but a substantive report on internal controls, which aligns with the definition of an Audit Report / Information (AR). The document length (12,167 characters) and detailed content confirm it is a full report rather than an announcement or a brief summary. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2019
2020-04-27 Chinese
2019年度独立董事述职报告（张继承）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2019 by an independent director of the company. It details the director's attendance at board meetings, opinions on company matters, committee work, on-site inspections, investor protection efforts, and training activities. The content is a narrative report on the director's duties and activities during the year rather than a financial report, audit, or regulatory filing. It is not an announcement or a brief notice but a detailed report on management/board activities. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their roles and responsibilities.
2020-04-27 Chinese
关于实际控制人拟减持股份的进展公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the progress of a planned shareholding reduction by the company's actual controller. It details the status of the share reduction plan, the shareholding before and after the reduction, and compliance with relevant securities laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about insider shareholding changes, specifically a progress update on a director's or controlling shareholder's share reduction plan. This fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2020-04-16 Chinese
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2020 First Quarter Performance Forecast" and provides estimated financial results for the period January 1 to March 31, 2020. It explicitly states that the forecast is unaudited and preliminary, with actual financial data to be disclosed in the forthcoming quarterly report. The document is short (848 characters) and serves as an announcement of expected financial performance rather than a full financial report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. Q1 2020
2020-04-09 Chinese
关于布洛芬颗粒通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kangzhi Pharmaceutical Co., Ltd. regarding the approval of their ibuprofen granules passing the generic drug consistency evaluation by the National Medical Products Administration. It includes product details, regulatory references, market impact, and risk warnings. The document is short (1354 characters) and serves as a regulatory announcement about a product approval and its implications rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it is a substantive announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about product approval and market impact without fitting other specific categories.
2020-04-08 Chinese
关于公司完成增加经营范围工商变更登记及《公司章程》备案的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from 康芝药业股份有限公司 regarding the completion of an increase in business scope and the filing of amendments to the company's Articles of Association. It includes details about the new business activities added, the updated business license information, and references to prior board and shareholder meeting resolutions. The document is relatively short (1253 characters) and serves as a formal notification of corporate changes rather than a detailed report or financial statement. There is no financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the change. The content fits best under Board/Management Information (MANG) as it relates to corporate governance changes and filings about the company's business scope and articles of association.
2020-03-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.